315 related articles for article (PubMed ID: 18848833)
1. Challenges to the therapeutic pipeline for irritable bowel syndrome: end points and regulatory hurdles.
Camilleri M; Chang L
Gastroenterology; 2008 Dec; 135(6):1877-91. PubMed ID: 18848833
[TBL] [Abstract][Full Text] [Related]
2. Drug development and IBS drugs: experience from the past, current challenges, and proposal for the future.
Camilleri M
Curr Opin Pharmacol; 2008 Dec; 8(6):671-6. PubMed ID: 18588997
[TBL] [Abstract][Full Text] [Related]
3. Irritable bowel syndrome: recent and novel therapeutic approaches.
Andresen V; Camilleri M
Drugs; 2006; 66(8):1073-88. PubMed ID: 16789793
[TBL] [Abstract][Full Text] [Related]
4. [Novel therapeutic approaches in the treatment of irritable bowel syndrome].
Pregun I; Herszényi L; Juhász M; Miheller P; Tulassay Z
Orv Hetil; 2007 May; 148(20):923-8. PubMed ID: 17509972
[TBL] [Abstract][Full Text] [Related]
5. Current and novel therapeutic options for irritable bowel syndrome management.
Camilleri M; Andresen V
Dig Liver Dis; 2009 Dec; 41(12):854-62. PubMed ID: 19665953
[TBL] [Abstract][Full Text] [Related]
6. Current and emerging treatments for irritable bowel syndrome with constipation and chronic idiopathic constipation: focus on prosecretory agents.
Thomas RH; Luthin DR
Pharmacotherapy; 2015 Jun; 35(6):613-30. PubMed ID: 26016701
[TBL] [Abstract][Full Text] [Related]
7. Emerging drugs for irritable bowel syndrome.
Bradesi S; Tillisch K; Mayer E
Expert Opin Emerg Drugs; 2006 May; 11(2):293-313. PubMed ID: 16634703
[TBL] [Abstract][Full Text] [Related]
8. Update on the Management of Diarrhea-Predominant Irritable Bowel Syndrome: Focus on Rifaximin and Eluxadoline.
Rivkin A; Rybalov S
Pharmacotherapy; 2016 Mar; 36(3):300-16. PubMed ID: 26971716
[TBL] [Abstract][Full Text] [Related]
9. New pharmacological treatment options for irritable bowel syndrome with constipation.
Nusrat S; Miner PB
Expert Opin Emerg Drugs; 2015; 20(4):625-36. PubMed ID: 26548544
[TBL] [Abstract][Full Text] [Related]
10. Evolution of clinical trials for irritable bowel syndrome: issues in end points and study design.
Trentacosti AM; He R; Burke LB; Griebel D; Kennedy DL
Am J Gastroenterol; 2010 Apr; 105(4):731-5. PubMed ID: 20372121
[TBL] [Abstract][Full Text] [Related]
11. Current medical treatments of dyspepsia and irritable bowel syndrome.
Camilleri M; Tack JF
Gastroenterol Clin North Am; 2010 Sep; 39(3):481-93. PubMed ID: 20951913
[TBL] [Abstract][Full Text] [Related]
12. The use of novel promotility and prosecretory agents for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation.
Gale JD
Adv Ther; 2009 May; 26(5):519-30. PubMed ID: 19444393
[TBL] [Abstract][Full Text] [Related]
13. FDA and EMA end points: which outcome end points should we use in clinical trials in patients with irritable bowel syndrome?
Corsetti M; Tack J
Neurogastroenterol Motil; 2013 Jun; 25(6):453-7. PubMed ID: 23672677
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic and therapeutic strategies in the irritable bowel syndrome.
Cremonini F; Talley NJ
Minerva Med; 2004 Oct; 95(5):427-41. PubMed ID: 15467518
[TBL] [Abstract][Full Text] [Related]
15. Irritable bowel syndrome: new and emerging therapies.
Harris LA; Chang L
Curr Opin Gastroenterol; 2006 Mar; 22(2):128-35. PubMed ID: 16462168
[TBL] [Abstract][Full Text] [Related]
16. Rifaximin for the treatment of irritable bowel syndrome.
Cremonini F; Lembo A
Expert Opin Pharmacother; 2012 Feb; 13(3):433-40. PubMed ID: 22251066
[TBL] [Abstract][Full Text] [Related]
17. Treatment options in irritable bowel syndrome.
Farthing MJ
Best Pract Res Clin Gastroenterol; 2004 Aug; 18(4):773-86. PubMed ID: 15324713
[TBL] [Abstract][Full Text] [Related]
18. Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study.
Dove LS; Lembo A; Randall CW; Fogel R; Andrae D; Davenport JM; McIntyre G; Almenoff JS; Covington PS
Gastroenterology; 2013 Aug; 145(2):329-38.e1. PubMed ID: 23583433
[TBL] [Abstract][Full Text] [Related]
19. [Pharmacological treatment of the irritable bowel syndrome: a technical review].
Remes-Troche JM; Gómez-Escudero O; Nogueira-de Rojas JR; Carmona-Sánchez R; Pérez-Manauta J; López-Colombo A; Sanjurjo-García JL; Noble-Lugo A; Chávez-Barrera JA; González-Martínez M
Rev Gastroenterol Mex; 2010; 75(1):42-66. PubMed ID: 20423782
[TBL] [Abstract][Full Text] [Related]
20. Current and future pharmacological treatments for diarrhea-predominant irritable bowel syndrome.
Camilleri M
Expert Opin Pharmacother; 2013 Jun; 14(9):1151-60. PubMed ID: 23621801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
